Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Etude de l’hétérogénéité inter-tumorale et intra-tumorale des gliomes de haut grade
2023Doctorant·e : Thiébaud Picart
Implication de la protéine de biogenèse des ribosomes Rsl24d1 dans l'homéostasie de cellules souches embryonnaires murines
2018Doctorant·e : Marion Bruelle
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
52
52 articles ont été cités au moins 52fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
12 245
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
449
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
174
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Claude Bernard Lyon 1 · Centre National de la Recherche Scientifique · Inserm
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prevalence, natural history and surgical outcome of spinal meningiomas in NF2-related schwannomatosis
2025ArticleJournal of Neuro-Oncology
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
2025ArticleBiomarker Research
Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation
2025ArticleNeuro-Oncology
Reply to “The time has come for an integrated and multiscale grading system for oligodendrogliomas IDH -mutant and 1p/19q co-deleted mixing imaging and histomolecular parameters”
2025ArticleNeuro-Oncology
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH ‐mutant and 1p/19q codeleted: A French POLA network study
2025ArticleCancer
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort
2025ArticleNeuro-Oncology
Survival outcomes associated with first-line procarbazine, CCNU, and Vincristine or Temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma
2025ArticleJournal of Clinical Oncology
PFMG2025–integrating genomic medicine into the national healthcare system in France
2025ArticleThe Lancet Regional Health - Europe
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL PIERRE WERTHEIMER - HCL
59 BD PINEL, 69677 BRON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2023
Nature communications · 2024
AbstractHere, the results of a phase 1/2 single-arm trial (NCT03744026) assessing the safety and efficacy of blood-brain barrier (BBB) disruption with an implantable ultrasound system in recurrent glioblastoma patients receiving carboplatin are reported. A nine-emitter ultrasound implant was placed at the end of tumor resection replacing the bone flap. After surgery, activation to disrupt the BBB was performed every four weeks either before or after carboplatin infusion. The primary objective of the Phase 1 was to evaluate the safety of escalating numbers of ultrasound emitters using a standard 3 + 3 dose escalation. The primary objective of the Phase 2 was to evaluate the efficacy of BBB opening using magnetic resonance imaging (MRI). The secondary objectives included safety and clinical efficacy. Thirty-three patients received a total of 90 monthly sonications with carboplatin administration and up to nine emitters activated without observed DLT. Grade 3 procedure-related adverse events consisted of pre syncope (n = 3), fatigue (n = 1), wound infection (n = 2), and pain at time of device connection (n = 7). BBB opening endpoint was met with 90% of emitters showing BBB disruption on MRI after sonication. In the 12 patients who received carboplatin just prior to sonication, the progression-free survival was 3.1 months, the 1-year overall survival rate was 58% and median overall survival was 14.0 months from surgery.
Neuro-oncology · 2024
Abstract The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients experience prolonged survival. However, treatment guidelines are often still based on information from historical series comprising both patients with IDH wild-type and IDH-mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological, and molecular factors associated with the outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with IDH-mutant grades 2 and 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize the overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Diagnostic and interventional imaging · 2026 · Journal Article
Koldeweij M, Picart T, Thomas L, Jupin-Delevaux E, et al.
European journal of nuclear medicine and molecular imaging · 2025 · Journal Article
Mair MJ, Lohmann P, Galldiks N, Belting M, et al.
Neuro-oncology · 2025 · Journal Article
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, et al.
Neuro-oncology · 2025 · Journal Article
Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, et al.
Bone · 2024 · Case Reports
Funck-Brentano T, Cohen-Solal M, Ducray F, Mandonnet E
Cancers · 2024 · Journal Article
Gkasdaris G, Berthiller J, Guyotat J, Jouanneau E, et al.
Neuro-oncology · 2024 · Journal Article
van den Bent MJ, French PJ, Brat D, Tonn JC, et al.
Minerva endocrinology · 2024 · Journal Article
DE Alcubierre D, Carretti AL, Ducray F, Jouanneau E, et al.
The New England journal of medicine · 2023 · Clinical Trial, Phase III
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, et al.
Clinical nuclear medicine · 2023 · Journal Article
Moreau A, Khayi F, Maureille A, Bonneville-Levard A, et al.
Cancers · 2023 · Journal Article
Gilhodes J, Meola A, Cabarrou B, Peyraga G, et al.
The American journal of surgical pathology · 2023 · Journal Article
Picart T, Poncet D, Barritault M, Bauchet L, et al.
The Lancet. Oncology · 2025 · Journal Article
Cloughesy TF, van den Bent MJ, Touat M, Blumenthal DT, et al.
Neuro-oncology · 2024 · Journal Article
Roth P, Gorlia T, Reijneveld JC, de Vos F, et al.
Journal of neuro-oncology · 2025 · Journal Article
Deboeuf L, Keraudy A, Picart T, Haddad G, et al.
European journal of endocrinology · 2024 · Journal Article
De Alcubierre D, Gkasdaris G, Mordrel M, Joncour A, et al.
Neuro-oncology · 2023 · Journal Article
Seyve A, Dehais C, Chinot O, Djelad A, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Published Erratum
Le Rhun E, Gorlia T, Felsberg J, Jongen J, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Multicenter Study
Le Rhun E, Gorlia T, Felsberg J, Jongen J, et al.
Journal of neuro-oncology · 2026 · Letter
Picart T, Ducray F
Annales d'endocrinologie · 2023 · Case Reports
De Rosa A, Calvanese F, Ducray F, Vasiljevic A, et al.
Biomarker research · 2025 · Journal Article
You B, Couraud S, Ceruse P, Badet L, et al.
Annales d'endocrinologie · 2023 · Case Reports
De Rosa A, Calvanese F, Ducray F, Vasiljevic A, et al.
Neuro-oncology advances · 2024 · Journal Article
Picca A, Di Stefano AL, Savatovsky J, Ducray F, et al.
Neuro-oncology · 2025 · Journal Article
Boele FW, Frances SM, Darlix A, Ducray F, et al.
Journal of neuro-oncology · 2026 · Letter
Picart T, Ducray F
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
Abstract Background hPG80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
Abstract Background hPG80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
European journal of cancer (Oxford, England : 1990) · 2024 · Clinical Trial, Phase II
Picca A, Touat M, Belin L, Gourmelon C, et al.
Journal of neurosurgery · 2024 · Randomized Controlled Trial
Picart T, Pallud J, Berthiller J, Dumot C, et al.
Nature communications · 2024 · Clinical Trial, Phase II
Carpentier A, Stupp R, Sonabend AM, Dufour H, et al.
Pharmaceutics · 2023 · Journal Article
Ducray F, Ramirez C, Robert M, Fontanilles M, et al.